^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) + onalespib (AT13387) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Excerpt:
...Patients must have histologically confirmed, BRAF-mutant (V600E/K) solid tumor...
Trial ID:
Source:
Title:
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors
Published date:
04/11/2023
Excerpt:
AT13387, in combination with dabrafenib and trametinib in BRAF V600E/K–mutant solid tumors...The best response was a partial response in two patients and stable disease in eight patients, with an overall response rate of 9.5% (90% exact confidence interval [CI], 2%-27%), a disease control rate of 47.6% (90% CI, 29%-67%), and a median overall survival of 5.1 months (90% CI, 3.4-7.6 months).
DOI:
https://doi.org/10.1002/cncr.34730
Trial ID:
Source:
Title:
CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors. Add to Collection
Published date:
05/13/2020
Excerpt:
HSP90 inhibition combined with BRAF/MEK inhibition was determined to be safe with evidence of disease control in a heavily pre-treated population of pts with BRAF V600E/K mut solid tumors.
DOI:
10.1200/JCO.2020.38.15_suppl.3609
Trial ID:
